Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00661531 Terminated - Breast Cancer Clinical Trials

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.

NCT ID: NCT00661102 Completed - Breast Cancer Clinical Trials

A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or adjuvant treatment of colorectal cancer. Patients who have been receiving oral Xeloda for at least 5 days will be randomized to receive prophylactic treatment with either placebo, topical corticosteroids or Bepantol. The anticipated time on study treatment is until disease progression or development of hand-foot syndrome, and the target sample size is 500+ individuals.

NCT ID: NCT00660803 Completed - Breast Cancer Clinical Trials

Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

Start date: May 2008
Phase: N/A
Study type: Observational

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

NCT ID: NCT00659906 Completed - Breast Neoplasm Clinical Trials

Optimizing Body Composition & Health After Breast Cancer

Start date: January 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to conduct a 12-month randomized controlled trial comparing the effects of strength training exercise to stretching and relaxation exercise (control) on body composition (bone, muscle and fat mass), energy balance, bone turnover, and physical function (strength, power, gait, balance and self-report physical function and symptoms) in women who experienced premature menopause from chemotherapy for breast cancer.

NCT ID: NCT00659373 Active, not recruiting - Breast Cancer Clinical Trials

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Co-SOFT
Start date: December 2007
Phase: Phase 3
Study type: Interventional

RATIONALE: Learning about the long-term effects of tamoxifen and ovarian function suppression on brain function may help doctors plan cancer treatment. PURPOSE: This study is looking at brain function in premenopausal women who are receiving tamoxifen with or without ovarian function suppression for early-stage breast cancer on clinical trial IBCSG-2402.

NCT ID: NCT00658281 Completed - Breast Cancer Clinical Trials

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

Start date: March 2008
Phase: N/A
Study type: Observational

The goal of this clinical research study is to use the On Board Imager kilovoltage (OBI KV) system and cone beam computed tomography (CBCT) scanning or CT-on-rail system to look at how well a routine device called an electronic portal imaging device (EPID) can set up a patient to receive radiation therapy on the lymph nodes in the neck.

NCT ID: NCT00657137 Terminated - Breast Cancer Clinical Trials

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

APRiCOT-B
Start date: April 2008
Phase: Phase 2
Study type: Interventional

This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2 expression in tumor tissue by IHC as a surrogate selection criterion for patients who will benefit from future treatment with apricoxib.

NCT ID: NCT00656669 Completed - Breast Cancer Clinical Trials

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Start date: April 2008
Phase: N/A
Study type: Interventional

The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. This treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading to other parts of the body. This study is being done to test the impact of adding sunitinib as a single-agent (Segment 1), followed by sunitinib plus paclitaxel (Segment 2), followed by doxorubicin and cyclophosphamide (Segment 3). We hope the addition of sunitinib will make the treatment more effective, but we don't know if this is true.

NCT ID: NCT00656604 Completed - Breast Cancer Clinical Trials

Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics

Start date: November 2003
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment. PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer.

NCT ID: NCT00656019 Completed - Breast Cancer Clinical Trials

Development of Vitamin D as a Therapy for Breast Cancer - Phase 2

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.